Fore Biotherapeutics
Our lead program focuses on plixorafenib, an investigational, next-generation BRAF inhibitor designed to inhibit a wide range of BRAF gene alterations in cancer cells beyond those targeted by earlier-generation BRAF inhibitors.
Private Company
Total funding raised: $443.5M
About
Our lead program focuses on plixorafenib, an investigational, next-generation BRAF inhibitor designed to inhibit a wide range of BRAF gene alterations in cancer cells beyond those targeted by earlier-generation BRAF inhibitors.
Small Molecules
Funding History
437Total raised:$443.5M
Grant$116K
Grant$280K
Grant$500K
Grant$426K